

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM346750

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Spectranetics Corporation		06/26/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Wells Fargo Bank, National Association		
Street Address:	1740 Broadway, MAC C7300-122		
City:	Denver		
State/Country:	COLORADO		
Postal Code:	80274		
Entity Type:	National Association: UNITED STATES		
PROPERTY NUMBERS Total: 19			
Property Type	Number	Word Mark	
Registration Number:	4638019		
Registration Number:	4243271	GLIDELIGHT	
Registration Number:	4522960	QUICK-ACCESS	
Registration Number:	4548605	QUICK-CROSS CAPTURE	
Registration Number:	4673064	SIGHTRAIL	
Registration Number:	4708930	SPECTRANETICS	
Registration Number:	4708931	SPECTRANETICS	
Registration Number:	4673065	TIGHTRAIL	
Registration Number:	4729002	TIGHTRAIL MINI	
Registration Number:	4712538	TURBO-BOOSTER	
Serial Number:	85687837	ALWAYS REACHING FARTHER	
Serial Number:	85687831		
Serial Number:	86541303	NETICS MEDICAL	
Serial Number:	85687806	SPECTRANETICS	
Serial Number:	86414400	SPNC	
Serial Number:	86441590	TURBO ELITE BTK	
Serial Number:	86369316	TURBO-TAPE	
Serial Number:	86278131	ENDURACOAT	
Serial Number:	85958731	STELLAREX	

CH \$490.00 4638019

CORRESPONDENCE DATA**Fax Number:** 4352143811*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 435-214-3807**Email:** mjones@markuswilliams.com**Correspondent Name:** Melinda Jones**Address Line 1:** 2750 Rasmussen Road, Suite H-104**Address Line 4:** Park City, UTAH 84098**ATTORNEY DOCKET NUMBER:** 10918.544**NAME OF SUBMITTER:** Melinda Jones**SIGNATURE:** /mej/**DATE SIGNED:** 07/02/2015**Total Attachments: 17**

source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page1.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page2.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page3.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page4.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page5.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page6.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page7.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page8.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page9.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page10.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page11.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page12.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page13.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page14.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page15.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page16.tif
source=Patent and Trademark Security Agreement - The Spectranetics Corporation#page17.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

This Patent and Trademark Security Agreement (this "Agreement"), dated as of June 26, 2015, is made by and between The Spectranetics Corporation, a Delaware corporation having a business location at the address set forth below next to its signature ("Company"), and Wells Fargo Bank, National Association ("Wells Fargo"), having a business location at the address set forth below next to its signature.

Recitals

Company and Wells Fargo are parties to a Credit and Security Agreement (as amended, supplemented or restated from time to time, the "Credit Agreement") dated as of February 25, 2011, setting forth the terms on which Wells Fargo may now or hereafter extend credit to or for the account of Company.

As a condition to extending credit to or for the account of Company, Wells Fargo has required the execution and delivery of this Agreement by Company.

ACCORDINGLY, in consideration of the mutual covenants contained in the Loan Documents and herein, the parties hereby agree as follows:

1. Definitions. All terms defined in the Recitals hereto or in the Credit Agreement that are not otherwise defined herein shall have the meanings given to them in the Credit Agreement. In addition, the following terms have the meanings set forth below:

"Patents" means all of Company's right, title and interest in and to U.S. patents or applications for U.S. patents, together with all fees or royalties with respect to each, and including without limitation the right to sue for past infringement and damages therefor, and licenses thereunder, all as presently existing or hereafter arising or acquired, including without limitation the patents listed on Exhibit A.

"Security Interest" has the meaning given in Section 2.

"Trademarks" means all of Company's right, title and interest in and to: (i) trademarks, service marks, collective membership marks, U.S. registrations and applications for U.S. registration for each, and the respective goodwill associated with each, (ii) licenses, fees or royalties with respect to each, (iii) the right to sue for past, present and future infringement, dilution and damages therefor, and (iv) licenses thereunder, all as presently existing or hereafter arising or acquired, including, without limitation, the marks listed on Exhibit B.

2. Security Interest. Company hereby irrevocably pledges and assigns to, and grants Wells Fargo a security interest (the "Security Interest") with power of sale to the extent permitted by law, in the Patents and in the Trademarks to secure payment of the Indebtedness. As set forth in the Credit Agreement, the Security Interest is coupled with a security interest in substantially all of the personal property of Company. This Agreement grants only the Security Interest herein described, is not intended to and does not affect any present transfer of title of any trademark registration or application and makes no assignment and grants no right to assign or

perform any other action with respect to any intent to use trademark application, unless such action is permitted under 15 U.S.C. § 1060.

3. Representations, Warranties and Agreements. Company represents, warrants and agrees as follows:

(a) **Existence; Authority.** Company is a corporation duly incorporated, validly existing and in good standing under the laws of its state of incorporation and this Agreement has been duly and validly authorized by all necessary corporate action on the part of Company.

(b) **Patents.** Exhibit A accurately lists all Patents owned by Company as of the date hereof, or to which Company has a right as of the date hereof to have assigned to it, and accurately reflects the existence of applications for Patents owned by Company as of the date hereof. If after the date hereof, Company owns, controls or has a right to have assigned to it any Patents not listed on Exhibit A, or if Exhibit A ceases to accurately reflect the existence and status of applications and letters patent pertaining to the Patents, then Company shall within 60 days provide written notice to Wells Fargo with a replacement Exhibit A, which upon acceptance by Wells Fargo shall become part of this Agreement.

(c) **Trademarks.** Exhibit B accurately lists all Trademarks owned by Company as of the date hereof and accurately reflects the existence of all applications for Trademark registrations as of the date hereof; provided, however, that Exhibit B need not list common law marks (i.e., Trademarks for which there are no applications or registrations) which are not material to Company's or any Affiliate's business(es). If after the date hereof, Company owns or controls any Trademarks not listed on Exhibit B (other than common law marks which are not material to Company's or any Affiliate's business(es)), or if Exhibit B ceases to accurately reflect the existence and status of applications and registrations pertaining to the Trademarks, then Company shall promptly provide written notice to Wells Fargo with a replacement Exhibit B, which upon acceptance by Wells Fargo shall become part of this Agreement.

(d) **Affiliates.** As of the date hereof, and except as indicated on Exhibit A, no Affiliate owns, controls, or has a right to have assigned to it any items that would, if such item were owned by Company, constitute Patents or Trademarks. If after the date hereof any Affiliate owns, controls, or has a right to have assigned to it any such items, then Company shall promptly either: (i) cause such Affiliate to assign all of its rights in such item(s) to Company; or (ii) notify Wells Fargo of such item(s) and cause such Affiliate to execute and deliver to Wells Fargo a patent and trademark security agreement substantially in the form of this Agreement.

(e) **Title.** Company has absolute title to each Patent and each Trademark listed on Exhibits A and B, free and clear of all Liens except Permitted Liens. Company (i) will have, at the time Company acquires any rights in Patents or Trademarks hereafter arising, absolute title to each such Patent or Trademark free and clear of all Liens except

Permitted Liens, and (ii) will keep all Patents and Trademarks free and clear of all Liens except Permitted Liens.

(f) **No Sale.** Except as permitted in the Credit Agreement, Company will not assign, transfer, encumber or otherwise dispose of the Patents or Trademarks, or any interest therein, without Wells Fargo's prior written consent.

(g) **Defense.** Company will at its own expense and using commercially reasonable efforts, protect and defend the Patents and Trademarks against all claims or demands of all Persons other than those holding Permitted Liens.

(h) **Maintenance.** Company will at its own expense maintain the Patents and the Trademarks to the extent reasonably advisable in its business including, but not limited to, filing all applications to obtain letters patent or trademark registrations and all affidavits, maintenance fees, annuities, and renewals possible with respect to letters patent, trademark registrations and applications therefor. Company covenants that it will not abandon nor fail to pay any maintenance fee or annuity due and payable on any Patent or Trademark, nor fail to file any required affidavit or renewal in support thereof, without first providing Wells Fargo: (i) sufficient written notice, of at least 30 days, to allow Wells Fargo to timely pay any such maintenance fees or annuities which may become due on any Patents or Trademarks, or to file any affidavit or renewal with respect thereto, and (ii) a separate written power of attorney or other authorization to pay such maintenance fees or annuities, or to file such affidavit or renewal, should such be necessary or desirable.

(i) **Wells Fargo's Right to Take Action.** If Company fails to perform or observe any of its covenants or agreements set forth in this Section 3, and if such failure continues for a period of ten (10) calendar days after Wells Fargo gives Company written notice thereof (or, in the case of the agreements contained in subsection (h), immediately upon the occurrence of such failure, without notice or lapse of time), or if Company notifies Wells Fargo that it intends to abandon a Patent or Trademark other than a Patent or Trademark that Company has reasonably determined is no longer useful in its business, Wells Fargo may (but need not) perform or observe such covenant or agreement or take steps to prevent such intended abandonment on behalf and in the name, place and stead of Company (or, at Wells Fargo's option, in Wells Fargo's own name) and may (but need not) take any and all other actions which Wells Fargo may reasonably deem necessary to cure or correct such failure or prevent such intended abandonment.

(j) **Costs and Expenses.** Except to the extent that the effect of such payment would be to render any loan or forbearance of money usurious or otherwise illegal under any applicable law, Company shall pay Wells Fargo on demand the amount of all moneys expended and all costs and expenses (including reasonable attorneys' fees and disbursements) incurred by Wells Fargo in connection with or as a result of Wells Fargo's taking action under subsection (i) or exercising its rights under Section 6, together with interest thereon from the date expended or incurred by Wells Fargo at the Default Rate.

(k) ***Power of Attorney.*** To facilitate Wells Fargo's taking action under subsection (i) and exercising its rights under Section 6, Company hereby irrevocably appoints (which appointment is coupled with an interest) Wells Fargo, or its delegate, as the attorney-in-fact of Company with the right (but not the duty) from time to time to create, prepare, complete, execute, deliver, endorse or file, in the name and on behalf of Company, any and all instruments, documents, applications, financing statements, and other agreements and writings required to be obtained, executed, delivered or endorsed by Company under this Section 3, or, necessary for Wells Fargo, after an Event of Default, to enforce or use the Patents or Trademarks or to grant or issue any exclusive or non-exclusive license under the Patents or Trademarks to any third party, or to sell, assign, transfer, pledge, encumber or otherwise transfer title in or dispose of the Patents or Trademarks to any third party. Company hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted herein shall terminate upon the termination of the Credit Agreement as provided therein and the payment and performance of all Indebtedness.

4. **Company's Use of the Patents and Trademarks.** Company shall be permitted to control and manage the Patents and Trademarks, including the right to exclude others from making, using or selling items covered by the Patents and Trademarks and any licenses thereunder, in the same manner and with the same effect as if this Agreement had not been entered into, so long as no Event of Default occurs and remains uncured.

5. **Events of Default.** Each of the following occurrences shall constitute an event of default under this Agreement (herein called "Event of Default"): (a) an Event of Default, as defined in the Credit Agreement, shall occur; or (b) Company shall fail promptly to observe or perform any covenant or agreement herein binding on it; or (c) any of the representations or warranties contained in Section 3 shall prove to have been incorrect in any material respect when made.

6. **Remedies.** Upon the occurrence of an Event of Default and at any time thereafter, Wells Fargo may, at its option, take any or all of the following actions:

(a) Wells Fargo may exercise any or all remedies available under the Credit Agreement.

(b) Wells Fargo may sell, assign, transfer, pledge, encumber or otherwise dispose of the Patents and Trademarks.

(c) Wells Fargo may enforce the Patents and Trademarks and any licenses thereunder, and if Wells Fargo shall commence any suit for such enforcement, Company shall, at the request of Wells Fargo, do any and all lawful acts and execute any and all proper documents required by Wells Fargo in aid of such enforcement.

7. **Miscellaneous.** This Agreement can be waived, modified, amended, terminated or discharged, and the Security Interest can be released, only explicitly in a writing signed by Wells Fargo. A waiver signed by Wells Fargo shall be effective only in the specific instance and for the specific purpose given. Mere delay or failure to act shall not preclude the exercise or

enforcement of any of Wells Fargo's rights or remedies. All rights and remedies of Wells Fargo shall be cumulative and may be exercised singularly or concurrently, at Wells Fargo's option, and the exercise or enforcement of any one such right or remedy shall neither be a condition to nor bar the exercise or enforcement of any other. All notices to be given to Company under this Agreement shall be given in the manner and with the effect provided in the Credit Agreement. Wells Fargo shall not be obligated to preserve any rights Company may have against prior parties, to realize on the Patents and Trademarks at all or in any particular manner or order, or to apply any cash proceeds of Patents and Trademarks in any particular order of application. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. Delivery of an executed counterpart of this Agreement by telefacsimile or other electronic means shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by telefacsimile or other electronic means also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement. This Agreement shall be binding upon and inure to the benefit of Company and Wells Fargo and their respective participants, successors and assigns and shall take effect when signed by Company and delivered to Wells Fargo, and Company waives notice of Wells Fargo's acceptance hereof. Wells Fargo may execute this Agreement if appropriate for the purpose of filing, but the failure of Wells Fargo to execute this Agreement shall not affect or impair the validity or effectiveness of this Agreement. A carbon, photographic or other reproduction of this Agreement or of any financing statement signed by Company shall have the same force and effect as the original for all purposes of a financing statement. This Agreement shall be governed by the internal law of Colorado without regard to conflicts of law provisions. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby. All representations and warranties contained in this Agreement shall survive the execution, delivery and performance of this Agreement and the creation and payment of the Indebtedness.


THE PARTIES WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED ON OR PERTAINING TO THIS AGREEMENT.

[The remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, the parties have executed this Patent and Trademark Security Agreement as of the date written above.

The Spectranetics Corporation
9965 Federal Drive
Colorado Springs, Colorado 80921

THE SPECTRANETICS CORPORATION

By: 
Name: Guy A. Childs
Its: Chief Financial Officer

Wells Fargo Bank, National Association
MAC C7300-122
1740 Broadway
Denver, Colorado 80274


WELLS FARGO BANK, NATIONAL ASSOCIATION

By: _____
Name: Dustin Jacobson
Its: Authorized Signatory

STATE OF COLORADO)
)
COUNTY OF EL PASO)

The foregoing instrument was acknowledged before me this 25th day of June, 2015, by Guy A. Childs, the Chief Financial Officer of The Spectranetics Corporation, a Delaware corporation, on behalf of the corporation.

BETTY J. WIGGINS
NOTARY PUBLIC
STATE OF COLORADO
Notary ID: 20044022093
My commission expires July 25, 2016


Notary Public

STATE OF COLORADO)
)
CITY AND COUNTY OF DENVER)

The foregoing instrument was acknowledged before me this ___ day of June, 2015, by Dustin Jacobson, an Authorized Signatory of Wells Fargo Bank, National Association, on behalf of the national association.

Notary Public

IN WITNESS WHEREOF, the parties have executed this Patent and Trademark Security Agreement as of the date written above.

The Spectranetics Corporation
9965 Federal Drive
Colorado Springs, Colorado 80921

THE SPECTRANETICS CORPORATION

By: _____
Name: Guy A. Childs
Its: Chief Financial Officer

Wells Fargo Bank, National Association
MAC C7300-122
1740 Broadway
Denver, Colorado 80274

WELLS FARGO BANK, NATIONAL ASSOCIATION

By: _____
Name: Dustin Jacobson
Its: Authorized Signatory

STATE OF COLORADO)
)
COUNTY OF EL PASO)

The foregoing instrument was acknowledged before me this ___ day of June, 2015, by Guy A. Childs, the Chief Financial Officer of The Spectranetics Corporation, a Delaware corporation, on behalf of the corporation.

Notary Public

STATE OF COLORADO)
)
CITY AND COUNTY OF DENVER)

The foregoing instrument was acknowledged before me this 25 day of June, 2015, by Dustin Jacobson, an Authorized Signatory of Wells Fargo Bank, National Association, on behalf of the national association.

Ann Coronado
Notary Public

ANN CORONADO
NOTARY PUBLIC
STATE OF COLORADO
NOTARY ID 20034024650
MY COMMISSION EXPIRES JULY 25, 2019

Signature Page to Patent and Trademark Security Agreement

EXHIBIT A

UNITED STATES ISSUED PATENTS

Patent Description	Registration Number	Registration Date
REENTRY CATHETER AND METHOD THEREOF	8,956,376	2/17/2015
REENTRY CATHETER AND METHOD THEREOF	8,998,936	4/7/2015
EXPANDABLE LASER CATHETER	8,465,480	6/18/2013
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,114,429	2/14/2012
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,128,951	3/6/2012
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,257,722	9/4/2012
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,491,925	7/23/2013
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,563,023	10/22/2013
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,673,332	3/18/2014

LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	8,734,825	5/27/2014
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	9,034,362	5/19/2015

UNITED STATES PATENT APPLICATIONS AND ADDITIONS

Patent Application	Application/Serial Number	Application/Filing Date
DILATOR SHEATH SET	14/195,692	3/3/2014
SHEATH	29/483,813	3/3/2014
SHEATH SET	29/483,815	3/3/2014
SYSTEM AND METHOD OF ABLATIVE CUTTING AND PULSED VACUUM ASPIRATION	13/800,651	3/13/2013
ALARM FOR LEAD INSULATION ABNORMALITY	13/799,894	3/13/2013
RETRACTABLE BLADE FOR LEAD REMOVAL DEVICE	13/834,405	3/15/2013
LASER CATHETER WITH HELICAL INTERNAL LUMEN	13/800,675	3/13/2013
ASSISTED CUTTING BALLOON	13/800,214	3/13/2013
DEVICE AND METHOD OF ABLATIVE CUTTING WITH HELICAL TIP	13/800,700	3/13/2013
TISSUE SLITTING METHOD AND SYSTEMS	13/828,231	3/14/2013
WIRE CENTERING SHEATH AND	13/798,985	3/13/2013

Patent Application	Application/Serial Number	Application/Filing Date
METHOD		
EXPANDABLE MEMBER FOR PERFORATION OCCLUSION	13/801,659	3/13/2013
INTELLIGENT CATHETER	13/804,812	3/14/2013
STABILIZATION DEVICE ASSISTED LEAD TIP REMOVAL	13/801,267	3/13/2013
ANGULAR OPTICAL FIBER CATHETER	13/800,864	3/13/2013
CATHETER MOVEMENT CONTROL	13/799,664	3/13/2013
LASER ABLATION CATHETER	13/800,728	3/13/2013
SMART MULTIPLEXED MEDICAL LASER SYSTEM	13/804,923	3/14/2013
THREADED LEAD EXTRACTION DEVICE	13/828,491	3/14/2013
LEAD REMOVAL SLEEVE	13/828,638	3/14/2013
EXPANDABLE LEAD JACKET	13/828,536	3/14/2013
MATERIAL CAPTURING GUIDEWIRE	13/801,149	3/13/2013
EXPANDABLE LASER CATHETER	13/898,093	5/20/2013
TISSUE SLITTING METHODS AND SYSTEMS	13/828,310	3/14/2013
TISSUE SLITTING METHODS AND SYSTEMS	13/828,383	3/14/2013
TISSUE SLITTING METHODS AND SYSTEMS	13/828,441	3/14/2013
CONTROLLER TO SELECT OPTICAL CHANNEL PARAMETERS IN A CATHETER	13/826,053	3/14/2013
NEEDLE AND GUIDEWIRE HOLDER	13/390,143	12/12/2011
DEVICE AND METHOD FOR CAPTURING	13/390,146	12/12/2011

Patent Application	Application/Serial Number	Application/Filing Date
GUIDEWIRES		
HYPOTUBE BASED SUPPORT CATHETER	13/390,140	12/12/2011
LASER CATHETER AND METHOD OF PERFORMING LASER ASSISTED THROMBOLYSIS	61/873,265	9/3/2013
ECCENTRIC BALLOON LASER CATHETER	14/175,359	2/7/2014
LASER-ASSISTED GUIDEWIRE HAVING A VARIABLE STIFFNESS SHAFT	13/737,573	1/9/2013
ENDOCARDIAL LEAD REMOVING APPARATUS	13/333,783	12/21/2011
ENDOCARDIAL LEAD CUTTING APPARATUS	11/187,553	1/22/2005
BIASING LASER CATHETER: MONORAIL DESIGN	14/152,334	1/10/2014
REENTRY CATHETER AND METHOD THEREOF	14/128,050	6/29/2012
CARDIOVASCULAR IMAGING SYSTEM	13/968,993	8/16/2013
RAPID EXCHANGE BIAS LASER CATHETER DESIGN	14/137,424	12/20/2013
DISTAL END SUPPORTED TISSUE SLITTING APPARATUS	14/192,445	2/27/2014
DUAL MODE MECHANICAL CATHETER CUTTING SYSTEM	61/987,993	5/2/2014
SURGICAL INSTRUMENT INCLUDING AN INWARDLY DEFLECTING CUTTING TIP FOR REMOVING AN IMPLANTED OBJECT	14/577,976	12/19/2014
TERAHERTZ SCANNING SYSTEM FOR AN INTRAVASCULAR SPACE	62/006,636	6/2/2014

Patent Application	Application/Serial Number	Application/Filing Date
CONVERTIBLE OPTICAL AND PRESSURE WAVE ABLATION SYSTEM AND METHOD	62/010,577	6/11/2014
MULTIPLE CONFIGURATION SURGICAL CUTTING DEVICE	62/094,808	12/19/2014
LASER ENERGY DELIVERY DEVICES INCLUDING LASER TRANSMISSION DETECTION SYSTEMS AND METHODS	62/072,323	10/29/2014
MEDICAL DEVICE FOR REMOVING AN IMPLANTED OBJECT	62/058,790	10/2/2014
RADIOPAQUE TAPE	29/513,415	12/30/2014
ELECTRODEPOSITION COATING FOR MEDICAL DEVICES	62/057,602	9/30/2014
RADIOPAQUE TAPE	29/513,414	12/30/2014
RADIOPAQUE TAPE	29/513,413	12/30/2014
RADIOPAQUE TAPE	29/513,412	12/30/2014
RADIOPAQUE TAPE	29/513,416	12/30/2014
COLLAPSING COIL COUPLING FOR LEAD EXTENSION AND EXTRACTION	62/098,214	12/30/2014
WIRE HOOK COUPLING FOR LEAD EXTENSION AND EXTRACTION	62/098,209	12/30/2014
MULTI-LOOP COUPLING FOR LEAD EXTENSION AND EXTRACTION	62/098,208	12/30/2014
LASER-INDUCED SHOCK WAVES FOR THE TREATMENT OF VASCULAR CONDITIONS	62/098,242	12/30/2014
LASER SCOOP DESOBLITERATION (LSD)- A NOVEL METHOD FOR MINIMAL INVASIVE REMOTE RECANALIZATION OF CHRONICALLY OCCLUDED	62/073,266	10/31/2014

Patent Application	Application/Serial Number	Application/Filing Date
SUPERFICIAL FEMORAL ARTERIES		
THROMBECTOMY AND SOFT DEBRIS REMOVAL DEVICE	14/562,014	12/5/2014
RETRACTABLE SEPARATING SYSTEMS AND METHODS	14/589,688	1/5/2015
REENTRY CATHETER AND METHOD THEREOF	14/584,851	12/29/2014
MEDICAL DEVICE FOR REMOVING AN IMPLANTED OBJECT	14/627,851	2/20/2015
MEDICAL DEVICE FOR REMOVING AN IMPLANTED OBJECT	14/627,950	2/20/2015
TAPERED LIQUID LIGHT GUIDE	14/613,949	2/4/2015
MEDICAL DEVICE FOR REMOVING AN IMPLANTED OBJECT	62/113,865	2/9/2015
MULTIPLE CONFIGURATION SURGICAL CUTTING DEVICE	14/635,742	3/2/2015
REENTRY CATHETER AND METHOD THEREOF	14/631,592	2/25/2015
MEDICAL DEVICE HANDLE	29/519,239	3/3/2015
MEDICAL DEVICE HANDLE	29/519,258	3/3/2015
MATERIAL REMOVAL CATHETER HAVING AN EXPANDABLE DISTAL END	14/700,550	4/30/2015
TISSUE SEPARATING SYSTEMS AND METHODS	14/682,779	4/9/2015
MATERIAL CAPTURING GUIDEWIRE	14/686,424	4/14/2015
AN ARCH SHAPED LASER CATHETER	14/438,176	10/24/2013
SEGMENTED BALLOON LASER ABLATION CATHETER	14/700,556	4/30/2015

Patent Application	Application/Serial Number	Application/Filing Date
REMOTE CONTROL SWITCH FOR A LASER SYSTEM	14/700,576	4/30/2015
INTRA-VASCULAR DEVICE WITH PRESSURE DETECTION CAPABILITIES USING PRESSURE SENSITIVE MATERIAL	14/714,925	5/18/2015
SYSTEM AND METHOD OF ABLATIVE CUTTING AND VACUUM ASPIRATION THROUGH PRIMARY ORIFICE AND AUXILIARY SIDE PORT	14/725,766	5/29/2015
SURGICAL INSTRUMENT FOR REMOVING AN IMPLANTED OBJECT	14/725,781	5/29/2015
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	12/558,420	9/11/2009
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	14/695,114	4/24/2015
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	14/032,336	9/20/2013
LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS	14/254,160	4/16/2014
POST-PROCESSING OF A MEDICAL DEVICE TO CONTROL MORPHOLOGY AND MECHANICAL PROPERTIES	13/926,515	6/25/2013
COATINGS FOR MEDICAL DEVICES	14/162,900	1/24/2014

EXHIBIT B


**UNITED STATES ISSUED TRADEMARKS, SERVICE MARKS
AND COLLECTIVE MEMBERSHIP MARKS**

REGISTRATIONS

Trademark	Registration Number	Registration Date
	4,638,019	November 11, 2014
GlideLight	4,243,271	November 13, 2012
QUICK-ACCESS	4,522,960	April 29, 2014
QUICK-CROSS CAPTURE	4,548,605	June 10, 2014
SIGHTRAIL	4,673,064	January 13, 2015
SPECTRANETICS	4,708,930	March 24, 2015
SPECTRANETICS	4,708,931	March 24, 2015
TIGHTRAIL	4,673,065	January 13, 2015

Trademark	Registration Number	Registration Date
TIGHTRAIL MINI	4,729,002	April 28, 2015
TURBO-BOOSTER	4,712,538	March 31, 2015

APPLICATIONS

Trademark Application	Application/Serial Number	Application Date
ALWAYS REACHING FARTHER	85/687,837	July 26, 2012
	85/687,831	July 26, 2012
NETICS MEDICAL	86/541,303	February 20, 2015
SPECTRANETICS	85/687,806	July 26, 2012
SPNC	86/414,400	October 3, 2014

Trademark Application	Application/Serial Number	Application Date
TURBO ELITE BTK	86/441,590	October 31, 2014
TURBO-TAPE	86/369,316	August 18, 2014
ENDURACOAT	86/278,131	May 12, 2014
Stellarex	85/958,731	June 13, 2013

COLLECTIVE MEMBERSHIP MARKS

NONE

UNREGISTERED MARKS

NONE